{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-046115","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2025-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.865638+00:00","generated_at":"2026-05-16T12:31:31.374010+00:00","sec_items":["1.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Galectin Therapeutics receives FDA alignment on belapectin trial design; secures $10M credit line","bullets":["FDA written response on belapectin shows alignment on patient population for registration trial; follow-up Type C meeting planned.","Follow-up meeting to finalize trial design and present biomarker data from AASLD meeting not included in prior submission.","Entered $10M unsecured, convertible line of credit from chairman Richard E. Uihlein; maturity extended to June 30, 2027.","Existing credit facilities also extended; company expects funding through at least March 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-046115","json":"https://secwatch.observer/filing/0001140361-25-046115.json","markdown":"https://secwatch.observer/filing/0001140361-25-046115.md","text":"https://secwatch.observer/filing/0001140361-25-046115.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036125046115/0001140361-25-046115-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036125046115/ef20061484_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:31:31.374010+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}